key: cord-0861144-y6dwo8zf
authors: Striley, Catherine W.; Hoeflich, Carolin C.
title: Converging public health crises: substance use during the coronavirus disease 2019 pandemic
date: 2021-05-17
journal: Curr Opin Psychiatry
DOI: 10.1097/yco.0000000000000722
sha: 407f4858d4e14d6b292b1d473233e3747739be0b
doc_id: 861144
cord_uid: y6dwo8zf

PURPOSE OF REVIEW: The international, public health crisis caused by the rapid spread of SARS-CoV-2 has resulted in unforeseen medical and psychiatric consequences. We reviewed publications from January 2020 to January 2021, given that earlier documents were not relevant, to review findings on changes in substance use and overdoses during the pandemic. Additionally, this review of the literature also documents advocacy efforts, health service modification and challenges, as well as COVID-related health complications associated with substance use. RECENT FINDINGS: Recent work focused on identifying changes in the distribution and use of substances as well as the unique challenges to promoting the health of persons who use substances in the current pandemic. Although COVID-19 has triggered unprecedented innovations in the organizational and public policy, the use of certain substances (alcohol, cannabis, cigarettes, fentanyl, heroin, and opiates) is increasing internationally. Unique associations between substance use and pandemic-related adverse health outcomes were identified. In addition, the pandemic precipitated significant barriers and disruptions to care. SUMMARY: Given increased overdose rates and infections among people who use drugs, continued surveillance and vigilance are needed to assess changes and reduce use and adverse consequences during the continuing COVID-19 crisis. Changes are urgently needed to reduce adverse health outcomes because of treatment barriers and lack of adequate treatment options. Additionally, integrative approaches are necessary to promote the public health of persons who use substances.

Coronavirus disease 2019 (COVID-19) has affected all aspects of our lives. Worldwide efforts to reduce the risk of drug overdoses and other adverse health outcomes among persons who use substances have been stopped, blocked and/or impeded. Unfortunately, the time lag in catching drug signals and their reporting makes it difficult to estimate the extent of the problem. Given our review of literature published during the first year of the pandemic, here we report on findings regarding the use of substances during the international spread of severe acute respiratory syndrome coronavirus 2.

Approximately 67 000 individuals in the United States died because of an overdose in 2018 [1]. Overdose fatality rates associated with heroin, methadone, and certain opioids experienced a reduction compared with the year prior [1]. However, rates of overdose fatalities associated with synthetic opioids sans methadone, cocaine, and stimulants, which may be used in a way, which could cause harm increased from 2017 to 2018 [1] . Thus, prompt action may be needed to ensure that fatal overdose rates continue to decline during the pandemic. However, implementation of public health interventions to reduce incidence of COVID-19 may have unintended health consequences for persons who use substances. For instance, South Africa's initiative placing individuals who are homeless in temporary housing may reduce their risk for & ]. Temporary abstinence could result in tolerance reversal; these individuals may be at an increased risk for drug overdose if they resume their prior dosage [2 & ]. Other adverse COVID-related health outcomes may be because of sociodemographic disparities, homelessness or housing insecurity, poverty or limited financial resources, social isolation, worsening mental or physiological health, reduced access to care, and unemployment or unstable employment. Persons who use substances may also be susceptible to changes in drug supply, accessibility, or cost. Thus, these dual epidemics require intensive and continuous monitoring to examine the impact of the COVID-19 pandemic on persons who use substances. The current review will describe changes in the use of substances during the pandemic, and specifically, the increase in overdose risks during the pandemic. We will highlight pandemic-caused health service modifications and COVID-related outcomes associated with substance use. Moreover, advocacy efforts in response to the pandemic will be elucidated.

In response to COVID-19, changes in substance use and use disorder have been observed worldwide. Among many populations, an increased risk for substance use and use disorders was identified. In China, nearly a third (32.1%) of individuals who reported regular alcohol ingestion divulged an increase in use [3 & ]. Relapses of alcohol consumption and cigarette smoking behaviors were seen among some persons who disclosed prior, 

The current COVID-19 pandemic may be associated with increased use of alcohol, cannabis, cigarettes, fentanyl, heroin and opiates, although not every study found an increase in use.

Persons who use substances may be at an increased risk for mortality or for hospitalization for adverse COVID-related events.

Implementations of government-mandated policies, specifically stay-at-home orders, may be associated with increases in overdoses.

Despite efforts to increase accessibility to substance use treatment options, several treatment barriers (e.g. closure or reduction of services) remain, which may negatively impact the health and wellbeing of persons who use substances during the COVID-19 pandemic. estimate for non-Hispanic White adults [13 & ]. Additionally, individuals with a substance use disorder and HIV were significantly more likely to be surrounded by other persons who use substances as well as miss at least two doses of HIV antiretroviral therapy per week during the pandemic vs. prior to COVID-19 [14 & ]. Moreover, mean confidence scores regarding maintenance of sobriety significantly dropped during the pandemic [14 & ]. This suggests that certain populations may be at a greater risk for increased substance use or negative health outcomes during the pandemic.

Given the importance of these findings that substance use increased during COVID-19 for some, the provocative finding of an increase in craving among residential patients, which is strongly predictive of both misuse and relapse, and the increase in poisoning/overdose, surveillance of trends in substance use is critical. Whether or not such surveillance will continue to be necessary postpandemic is almost a moot point. With authorities changing regulations and laws, and with suppliers creating new formulations, ongoing, real-time surveillance is always required. Prior work also examined differences in overdoses prior to and after the implementation of stayat-home orders (SAHOs) and other governmentmandated lockdowns. When comparing emergency medical service data prior to and after Indianapolis's SAHO, service calls related to overdoses and deaths because of overdoses both increased Table 1 . 

Some publications addressed the structural and individual-level barriers to care as well as the organizations' response to these challenges. Although individuals with a history of an overdose or any substance use disorder could be more likely to experience a COVID-related admission to an ICU [24 && ], persons who use substances may be unfamiliar with available resources, which could mitigate risk for harmful health consequences because of substance use in the pandemic. In three Norwegian cities, only a fourth (24.3%) of interviewees who use substances endorsed knowledge of COVID-19 services for persons who use drugs [26] . This lack of knowledge is compounded by the decline of services and programs for substance use treatment and management during the pandemic. North American Syringe Exchange Network (NASEN) data revealed that syringe service programs reported a reduction in medication and treatment services In addition to structural challenges, other barriers to providing adequate and timely substance use treatment may include patient-level factors. A cohort study identified an increase in the proportion of patients seen by the Tucson Fire Department who refused transport to emergency departments during COVID-19 vs. pre-COVID-19 [29 & ]. Among patients who received naloxone, the refusal rate more than doubled from before vs. during the pandemic [29 & ]. This suggests that a myriad of challenges may be present, limiting the ability for persons who use substances to be able to receive appropriate treatment and management resources for their substance use.

To combat these challenges, some policy changes have already been established and implemented at an organizational level to provide necessary treatment and services to persons who use substances. For instance, several syringe services programs in the United States offered information on how they pivoted to continue to provide harm reduction during the pandemic by offering delivery or mail services for persons who inject drugs [ ADVOCACY COVID-19 resulted in detrimental health implications for populations worldwide. Early in the pandemic, authors attempted to forecast problems from the pandemic among people who use drugs. These authors wrote to support efforts to empower people who use drugs to receive adequate treatment to revise substance management services for challenges related to mitigation, or to suggest ways to reduce risk of COVID exposure. Guidance was provided to people who use substances through the International Network of People who Use Drugs [34] . This organization offered advice on techniques to lessen the risk of coronavirus transmission during substance procurement and use [34] and advocated for policy changes to reduce harm related to substance use [35 & ].

Health professionals and organizations were also urged to change their practice during COVID-19. Mackolil and Mackolil [36] advised mental health providers to consider COVID-related stress and frustration, feelings of hopelessness, maladaptive-coping strategies, and changes in drug availability when planning treatment for mental health and substance use disorders. Stowe et al. ] encouraged implementation of overdose prevention programs and increased naloxone provision, especially to community members dependent on opioids. In addition to increased community access to harmreduction strategies, structural changes to foster greater methadone and buprenorphine utilization were proposed [37] . Modifying regulations for buprenorphine-prescribing practices, distributing federal funds to promote treatment accessibility, and facilitating methadone provision through pharmacies were promoted [37] . To limit in-person contact and increase access to care during the pandemic, modifications to the treatment and management of substance use and use disorders were suggested to minimize risk of SARS-COV-2 transmission [37] . These authors anticipated problems caused by the pandemic that might affect people who use drugs and advocated for changes to reduce negative effects.

Although the COVID-19 pandemic has prompted innovations in the care and treatment of persons who use substances [31] , continued surveillance is urgently needed to examine trends in substance use patterns during the pandemic. Published [36] . Thus, a timely and increasing need is present to assess international trends in substance use and overdoses among these marginalized populations during the pandemic. This work could be critical in guiding policy development to ensure identification and implementation of integrative and evidence-based strategies to promote public health in the shadow of these converging epidemics. 

There are no conflicts of interest. -19 fear, mental health, and substance misuse conditions among university social work students in Israel and Russia. Int J Ment Health Addict 2020; 1-8; https://doi.org/10.1007/ s11469-020-00360-7. Researchers found that some students who used alcohol, cannabis, or cigarettes before the pandemic disclosed an increase in use during COVID-19.

5.

Winkler P, Formanek T, Mlada K, et al. Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide crosssectional surveys. Epidemiol Psychiatr Sci 2020; 29:e173. Adults from the Czech Republic participated in computer-assisted interviews via the web or telephone to examine the percentage of individuals with a mental health or substance use disorder. When comparing 2017 to 2020 data, the prevalence of any type of mental health disorder, anxiety disorder, and suicidality rose whereas alcohol use disorders declined. This retrospective study revealed an increase in emergency department visits associated with alcohol abuse when comparing Italy's re-opening period to a year prior in a sample of adolescents and young adults.

& Arya S, Gupta R. COVID-19 outbreak: challenges for addiction services in India. Asian J Psychiatr 2020; 51:102086. This letter to the editor discussed some barriers to providing effective substance use treatment services to residents of India, including limited public transport, changes in alcohol availability, and uncertain telehealth service acceptability.

& Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul Health Manag 2021; 24(S1):S43-s51. The findings of this study indicated that compared with before the pandemic, significant increases were observed in positivity rates for heroin, fentanyl, and opiates during the pandemic.

Ochalek Using a survey to assess how the current pandemic impacted the delivery of substance use treatment and management services, this study found that nearly half (48.1%) of clinics offered both remote and in-person options for follow-up appointments regarding medications for persons with opioid use disorder.

Racial and ethnic disparities in the prevalence of stress and worry, mental health conditions, and increased substance use among adults during the COVID-19 pandemic -United States

Potential influences of the COVID-19 pandemic on drug use and HIV care among people living with HIV and substance use disorders: experience from a Pilot mHealth intervention

This study suggested that participants were twice as likely to use illicit drugs

Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic

Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic

Refusals after prehospital administration of naloxone during the COVID-19 pandemic

This study found that patients who were provided naloxone by Emergency Medical Services personnel during the pandemic were 2

Twenty harm reduction centers in Spain were assessed for changes in treatment services because of the pandemic. The distribution of methadone rose when comparing

Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19

Patient factors associated with SARS-CoV-2 in an admitted emergency department population

COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

This case-control study found that the mortality rate among persons with COVID-19 positivity and a lifetime substance use disorder diagnosis was significantly higher for blacks than whites

COVID-19 crisis: harm reduction resources for people who use drugs

This commentary discussed COVID-related challenges for persons who use substances and provided detailed recommendations proposed by the International Network of People who use Drugs

Addressing psychosocial problems associated with the COVID-19 lockdown

An overdose surge will compound the COVID-19 pandemic if urgent action is not taken